ACHV — Achieve Life Sciences Share Price
Last trade - 00:00- $112.73m
- $99.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.39 | ||
| Price to Tang. Book | 12.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -228.71% | ||
| Return on Equity | -154.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 22.56 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
Directors
- Richard Stewart CHM (62)
- Cindy Jacobs PRE (63)
- John Bencich CEO (43)
- Jerry Wan CAO (39)
- Anthony Clarke CSO (65)
- Donald Joseph LED (67)
- Bridget Martell IND (55)
- Martin Mattingly IND (64)
- Jay Moyes IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- March 22nd, 1995
- Public Since
- October 12th, 1995
- No. of Shareholders
- 11
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 34,685,072
- Address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, 98021
- Web
- https://achievelifesciences.com/
- Phone
- +1 4256861500
- Contact
- Nicole Jones
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ACHV
Upcoming Events for ACHV
Achieve Life Sciences Inc Annual Shareholders Meeting
Achieve Life Sciences Inc Annual Shareholders Meeting
Q2 2025 Achieve Life Sciences Inc Earnings Release
Q3 2025 Achieve Life Sciences Inc Earnings Release
Similar to ACHV
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
Adaptimmune Therapeutics
NASDAQ Capital Market
FAQ
As of Today at 19:03 UTC, shares in Achieve Life Sciences are trading at $3.08. This share price information is delayed by 15 minutes.
Shares in Achieve Life Sciences last closed at $3.08 and the price had moved by -39.25% over the past 365 days. In terms of relative price strength the Achieve Life Sciences share price has underperformed the S&P500 Index by -45.93% over the past year.
The overall consensus recommendation for Achieve Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAchieve Life Sciences does not currently pay a dividend.
Achieve Life Sciences does not currently pay a dividend.
Achieve Life Sciences does not currently pay a dividend.
To buy shares in Achieve Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.08, shares in Achieve Life Sciences had a market capitalisation of $106.83m.
Here are the trading details for Achieve Life Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACHV
Based on an overall assessment of its quality, value and momentum Achieve Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Achieve Life Sciences is $14.50. That is 370.78% above the last closing price of $3.08.
Analysts covering Achieve Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$1.24 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achieve Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -28.32%.
As of the last closing price of $3.08, shares in Achieve Life Sciences were trading -17.54% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Achieve Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Achieve Life Sciences' management team is headed by:
- Richard Stewart - CHM
- Cindy Jacobs - PRE
- John Bencich - CEO
- Jerry Wan - CAO
- Anthony Clarke - CSO
- Donald Joseph - LED
- Bridget Martell - IND
- Martin Mattingly - IND
- Jay Moyes - IND